EGFR Protein, Human, Recombinant (His), AF488-Labeled

1. Immobilized EGF Protein, Human, Recombinant (hFc) (Cat#TMPY-01062) at 2 μg/mL (100 μl/well) can bind EGFR Protein, Human, Recombinant (His), AF488-Labeled (Cat#TMPY-06990), the EC50 is 100-300 ng/mL.
2. Flow cytometric analysis of anti-EGFR CAR expression. 293 cells were lentivirally transduced with anti-EGFR CAR. Flow cytometric analysis was performed with a negative control protein and EGFR Protein, Human, Recombinant (His), AF488-Labeled (Cat#TMPY-06990), respectively. Non-transduced 293 cells were used as a control (left).
3. Binding activity of AF 488-conjugated EGFR protein to PBMC cells. PBMC cells were stained with anti-CD3 antibody and EGFR Protein, Human, Recombinant (His), AF488-Labeled (Cat#TMPY-06990) and detected by flow cytometry. PBMC cells stained with anti-CD3 antibody were used as a control (left).

EGFR Protein, Human, Recombinant (His), AF488-Labeled is expressed in HEK293 Cells. The accession number is P00533.

Human

HEK293 Cells

≥ 90% as determined by SDS-PAGE.

As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy